Regeneron PharmaceuticalsSTU:RGO +1.76%85 Net Margin % is 20.17% as of Mar. 2026, which is 37% below its 10-year median of 31.84. GuruFocus rates STU:RGO with a GF Score™ of 85/100 and a GF Value™ of €788.02 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 946 Biotechnology companies, Regeneron Pharmaceuticals ranks better than 90.8% on this metric.
The historical rank and industry rank for Regeneron Pharmaceuticals's Net Margin % or its related term are showing as below:
STU:RGO'
s Net Margin % Range Over the Past 10 Years
Min: 18.42 Med: 31.84 Max: 50.25
Current: 29.65
STU:RGO's Net Margin % is ranked better than 90.8% of 946
companies
in the Biotechnology industry
Industry Median: -88.815
vs STU:RGO: 29.65
Regeneron Pharmaceuticals (STU:RGO) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Regeneron Pharmaceuticals Net Margin % Related Terms
Regeneron Pharmaceuticals Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:RGO vs ALNY, RVMD, ONC: Net Margin % Comparison
For the Biotechnology subindustry, Regeneron Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regeneron Pharmaceuticals Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Net Margin % distribution charts can be found below:
* The bar in red indicates where Regeneron Pharmaceuticals's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regeneron Pharmaceuticals (STU:RGO) has a Net Margin % of 20.17% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Regeneron Pharmaceuticals and its competitors. This is 37% below median its historical median of 31.84. Over the past decade, Regeneron Pharmaceuticals' Net Margin % has ranged from 18.42 to 50.25. According to the industry distribution chart, Regeneron Pharmaceuticals ranks #87 out of 946 companies in the Biotechnology industry, placing it in the top 9.2%.
Is Regeneron Pharmaceuticals' Net Margin % too high?
Regeneron Pharmaceuticals' current Net Margin % of 20.17% is 37% below median its 10-year median of 31.84. Over the past 10 years, this metric has ranged from a low of 18.42 to a high of 50.25. Based on the distribution chart, Regeneron Pharmaceuticals ranks #87 out of 946 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Regeneron Pharmaceuticals has a GF Score™ of 85/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Regeneron Pharmaceuticals' Net Margin % compare to ALNY and RVMD?
According to the Biotechnology industry distribution chart, Regeneron Pharmaceuticals ranks #87 out of 946 companies for Net Margin %. This places Regeneron Pharmaceuticals in the top 9% of its industry — outperforming the majority of peers. Historically, Regeneron Pharmaceuticals' own Net Margin % has ranged from 18.42 to 50.25 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Regeneron Pharmaceuticals and its competitors. Regeneron Pharmaceuticals's current Net Margin % is 20.17%, which is 37% below median its own 10-year median of 31.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regeneron Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals (STU:RGO) is currently considered Significantly Undervalued. The stock's GF Value™ is €788.02, compared to a current price of €554.60 — trading 29.6% below its estimated fair value. The current Net Margin % is 20.17%, which is 37% below median its 10-year median of 31.84. Regeneron Pharmaceuticals' overall GF Score™ is 85/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Regeneron Pharmaceuticals (STU:RGO), the current Net Margin % is 20.17% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Regeneron Pharmaceuticals (STU:RGO) Overvalued in 2026?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals stock appears to be undervalued.
The current stock price of €554.60 is trading 29.6% below its estimated GF Value™ of €788.02.
GuruFocus considers Regeneron Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for STU:RGO:
Net Margin %: 20.17% (37% below median its 10-year median of 31.84)
GF Value™: €788.02 vs. price of €554.60 (29.6% below fair value)
No single metric tells the full story. See the STU:RGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
85GF Score
Get the complete analysis for STU:RGO
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:RGO has been successfully added to your 
